

Rhinitis, sinusitis, and upper airway disease

A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis

Warner Carr, MD,^a Jonathan Bernstein, MD,^b Phil Lieberman, MD,^c Eli Meltzer, MD,^d Claus Bachert, MD, PhD,^e David Price, MD,^f Ullrich Munzel, MD, PhD,^g and Jean Bousquet, MD, PhD^h *Mission Viejo and San Diego, Calif, Cincinnati, Ohio, Memphis, Tenn, Ghent, Belgium, Aberdeen, United Kingdom, Bad Homburg, Germany, and Montpellier, France*

Background: Moderate-to-severe allergic rhinitis (AR) is a challenge to treat, with many patients using multiple therapies and achieving limited symptom control. More effective therapies must be developed and tested in well-controlled,

randomized, prospective studies with a direct comparison to current standards.

Objectives: The aim of these studies was to investigate the efficacy of MP29-02 (a novel formulation of azelastine and fluticasone propionate [FP]) in patients with moderate-to-severe seasonal allergic rhinitis (SAR) and to compare its efficacy with 2 first-line therapies (ie, intranasal azelastine and intranasal FP) in this population.

Methods: Three thousand three hundred ninety-eight patients (≥ 12 years old) with moderate-to-severe SAR were enrolled into 3 multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group trials (MP4002 [NCT00651118], MP4004 [NCT00740792], and MP4006 [NCT00883168]). Each trial was conducted for 14 days during different allergy seasons. The primary efficacy variable was the sum of the morning and evening change from baseline in reflective total nasal symptom score (range, 0-24) over the treatment period. Outcomes for the meta-analysis included efficacy according to disease severity and time to response in relevant responder criteria.

Results: In the meta-analysis MP29-02 reduced the mean reflective total nasal symptom score from baseline (-5.7 [SD, 5.3]) more than FP (-5.1 [SD, 4.9], $P < .001$), azelastine (-4.4 [SD, 4.8], $P < .001$), or placebo (-3.0 [SD, 4.2], $P < .001$). This benefit was observed from the first day of assessment, with improvement in each individual nasal symptom, even in the patients with the most severe disease. MP29-02 achieved response consistently days earlier and showed greater efficacy in patients with moderate-to-severe rhinitis than FP and azelastine.

Conclusions: MP29-02 represents a novel therapy that demonstrated superiority to 2 first-line therapies for AR. Patients with moderate-to-severe SAR achieved better control, and their symptoms were controlled earlier with MP29-02 than with recommended medications according to guidelines. (*J Allergy Clin Immunol* 2012;129:1282-9.)

Key words: Allergic rhinitis, azelastine, fluticasone propionate, MP29-02, moderate-to-severe

From ^aAllergy and Asthma Associates of Southern California, Mission Viejo; ^bthe Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati; ^cthe Department of Internal Medicine & Pediatrics, University of Tennessee College of Medicine, Memphis; ^dthe Allergy and Asthma Medical Group and Research Center, San Diego; ^ethe Department of Oto-Rhino Laryngology, Ghent University Hospital; ^fthe Department of General Practice & Primary Care, University of Aberdeen; ^gMEDA Pharma GmbH & Co. KG, Biostatistics & Information, Bad Homburg; and ^hthe Department of Respiratory Diseases, Hôpital Arnaud de Villeneuve University Hospital, Montpellier, and INSERM CSP1018.

These studies were funded by Meda Pharmaceuticals, Inc, and were designed to be consistent with recommendations provided in the US Food and Drug Administration guidance document for clinical development of drug products for allergic rhinitis (Guidance for Industry, US Department of Health and Human Services, US Food and Drug Administration Center for Drug Evaluation and Research; April 2000).

Disclosure of potential conflict of interest: W. Carr has consulted for and received research support from MEDA, Alcon, and Ista. J. Bernstein has received research support from Meda and Dynova; is on the Board of Directors and a Fellow of the American Association of Allergy, Asthma & Immunology (AAAAI); is a Fellow at the American College of Allergy, Asthma & Immunology (ACAAI); and is Chairman of the Allergists for Israel (AFI). P. Lieberman is an advisor for the Allergy Foundation of America and Baxter and has given lectures for MEDA, Genentech, Ista, and TEVA. E. Meltzer has received research support from Amgen, Apotex, HRA, MedImmune, Schering-Plough, Alcon, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Proctor & Gamble, Sunovion (Sepracor), and Teva; is a consultant and/or is on the advisory board for Alcon, AstraZeneca, Bausch & Lomb, Dey, Forest, Ista, Johnson & Johnson, Meda, Merck, ONO Pharma, OptiNose, Proctor & Gamble, Rady Children's Hospital, Rigel, Sanofi-Aventis, Sepracor, Stallergenes, Teva, Alexa, Boehringer Ingelheim, Kalypsys, and Sunovion; is a speaker for the AAAAI, Alcon, Allergists for Israel, Dey, Florida Allergy Asthma Immunology Society, Ista, Sepracor, Teva, Merck, and Sunovion; and has provided expert designation in legal matters for Aventis Pharmaceuticals and Sanofi Aventis v. Barr Laboratories, Fexofenadine. D. Price has received consultancy and speaker fees from Merck, Mundipharma, Novartis, Medapharma, Kyorin, and TEVA; has received consultancy fees from GlaxoSmithKline, Almirall, and Chiesi; has received consultancy fees and grants from Pfizer, and AstraZeneca; has received consultancy and speakers' fees and grants from Boehringer Ingelheim; has received speakers' fees and grants from Aerocrine; has received grants from the UK National Health Service, Nycomed, and Medapharma; is director of Research in Real Life Ltd; is a guideline group member for Allergic Rhinitis and its Impact on Asthma and EPOS; is a research committee member for International Primary Care Respiratory Group; and has shares in AKL Ltd. J. Bousquet has received honoraria from Stallergenes, Actelion, Almirall, AstraZeneca, Chiesi, GlaxoSmithKline, Merck, Novartis, OM Pharma, Sanofi, TEVA, and Uriach. The rest of the authors declare that they have no relevant conflicts of interest.

Received for publication August 23, 2011; revised December 15, 2011; accepted for publication January 19, 2012.

Available online March 13, 2012.

Corresponding author: Warner Carr, MD, Allergy and Asthma Associates of Southern California, 27800 Medical Center Rd, Suite 244, Mission Viejo, CA 92691. E-mail: wcarr@allergee.com.

0091-6749/\$36.00

© 2012 American Academy of Allergy, Asthma & Immunology

doi:10.1016/j.jaci.2012.01.077

Allergic rhinitis (AR) occurs in more than 500 million persons around the world and is a global health problem that causes major illness and disability.^{1,2} The effects of AR are far reaching and easily underestimated, with its negative effects affecting patient's quality of life (QoL)³ and school and work performance.^{4,5} It is also a costly disease, estimated at €4260 per patient per year in Europe,⁶ and \$3.4 billion annually in the United States in direct medical costs alone.⁷

AR is a challenge to treat because many patients do not respond sufficiently to treatment. Furthermore, the disease severity is

Abbreviations used

ANCOVA:	Analysis of covariance
AR:	Allergic rhinitis
FP:	Fluticasone propionate
iTNSS:	Instantaneous total nasal symptom score
QoL:	Quality of life
RQLQ:	Rhinitis Quality of Life Questionnaire
rTNSS:	Reflective total nasal symptom score
rTOSS:	Reflective total ocular symptom score
SAR:	Seasonal allergic rhinitis

underestimated and, consequently, inadequately treated.⁸ Most patients have moderate-to-severe disease,^{3,9} frequently experience severe symptoms while receiving therapy, and are dissatisfied and noncompliant with currently available therapy.^{10,11} Patients use multiple therapies (as many as 74.4% of patients) in an attempt to achieve symptom control,^{3,9,12-14} despite the limited evidence to support this practice.²

Given this unmet medical need, more effective therapies for the management of AR are clearly required. Current guideline-based therapy for AR includes oral and intranasal antihistamines and intranasal corticosteroids. Although intranasal corticosteroids are considered the most effective therapy, especially for more severe cases,^{2,15} they need some time to become effective. In contrast, intranasal H₁-antihistamines, such as azelastine, have a rapid onset of action.

The recently updated Allergic Rhinitis and its Impact on Asthma guidelines¹⁵ highlighted the need for high-quality, direct comparison studies to further substantiate the current treatment recommendations. Three randomized, placebo- and active-controlled, parallel-group trials were performed to directly compare the efficacy and safety of intranasal azelastine, intranasal fluticasone propionate (FP), and intranasal MP29-02 (a novel formulation of azelastine and FP), with all 3 medications using exactly the same formulation, in patients with moderate-to-severe seasonal allergic rhinitis (SAR). Each study aimed to demonstrate and replicate that MP29-02 demonstrated superiority to either monotherapy in a head-to-head fashion. Moreover, in the meta-analysis responder analyses were added to further address relevance in treatment efficacy.

METHODS

Protocol

Individual results and a meta-analysis of 3 phase III, multicenter, randomized, double-blind, parallel-group trials (MP4002 [NCT00651118], MP4004 [NCT00740792], and MP4006 [NCT00883168]) were assessed in patients with moderate-to-severe SAR to determine the efficacy of MP29-02 compared with intranasal H₁-antihistamine (azelastine), corticosteroid (FP), and placebo using the same formulation. Placebo spray comprised exactly the same vehicle/formulation as the active treatments without any active agent. The same treatments and treatment periods and essentially similar protocols were used in the 3 studies. The studies were conducted in accordance with US Food and Drug Administration and European Medicines Agency recommendations,^{16,17} and good clinical practice¹⁸ during the 2008-2009 US Spring and Fall allergy seasons. After institutional review board approval, written informed consent was obtained from all patients or legal guardians (subjects aged <18 years).

Participants

Subjects (≥12 years old) with a minimum 2-year history of SAR, significant current clinical rhinitis symptomatology, and a positive skin prick test response

to relevant pollen were randomized. All subjects had moderate-to-severe SAR defined by a reflective total nasal symptom score (rTNSS) of at least 8 of 12, with a congestion score of 2 or 3 during screening. Inclusion criteria for the duration of symptoms for the 3 studies were slightly different. For more information on this and exclusion criteria, see the Methods section in this article's Online Repository at www.jacionline.org. Excluded therapies and medications are summarized in Table E1 in this article's Online Repository at www.jacionline.org.

Planned interventions and timing

Each study comprised a 7-day, single-blind, placebo lead-in period and a 14-day treatment period with 3 study visits at days 1, 7, and 14. On visit 2 (day 1), eligible patients were randomized to 14 days of treatment (1 spray per nostril twice daily) with the following: (1) MP29-02 nasal spray (novel formulation of 137 μg of azelastine/50 μg of FP); (2) azelastine nasal spray (137 μg); (3) FP (50 μg) nasal spray; or (4) vehicle placebo nasal spray. Doses were separated by approximately 12 hours. Patients recorded application times and symptom scores in a diary. Compliance with treatment was assessed (see the Methods section in this article's Online Repository).

Efficacy variables

The primary efficacy variable was the sum of the morning and evening overall change from baseline in 12-hour rTNSSs over the entire 14-day treatment period (sum of the individual nasal symptoms of congestion, itching, rhinorrhea, and sneezing).^{16,17} All nasal and ocular symptoms were scored by patients twice daily on each treatment day according to a 4-point scale. For nasal symptoms, a score of 0 was defined as none (no symptoms present), a score of 1 was defined as mild (mild symptoms that do not interfere with any activity), a score of 2 was defined as moderate (slightly bothersome symptoms that slightly interfere with activity/nighttime sleep), and a score of 3 was defined as severe (bothersome symptoms that interfere with activity/nighttime sleep). Therefore the maximum rTNSS or instantaneous total nasal symptom score (iTNSS) was 24 (ie, 4 symptoms × score of 3 × 2 for morning + evening). See the Methods section in this article's Online Repository for calculation of baseline scores.

Secondary efficacy variables included overall change from baseline (treatment period, days 2-14) in the individual reflective nasal symptom score, iTNSS, and reflective total ocular symptom score (rTOSS). For the symptoms of itchy eyes and watery eyes, the same scale was used as for nasal symptoms. For the symptom of red eyes, the following scale was used: 0, none (no redness present); 1, mild (slightly dilated blood vessels and pinkish color compared with the subject's normal color); 2, moderate (more dilation of blood vessels and red color compared with subject's normal color); and 3, severe (large, numerous, dilated blood vessels and deep red color compared with the subject's normal color). The maximum rTOSS was 18 (ie, 3 symptoms × score of 3 × 2 for morning + evening). Onset of action was also determined clinically by means of assessment of iTNSS in the first 4 hours after administration.

QoL

QoL was assessed before randomization and at the end of the study by using the 28-item Rhinitis Quality of Life Questionnaire (RQLQ) for subjects older than 18 years.¹⁹ Total baseline RQLQ scores were used to categorize patients according to severity.

Safety variables

Safety was assessed based on the incidence, type, and severity of adverse events coded with the Medical Dictionary for Regulatory Activities. At each visit, patients underwent a direct visual nasal examination to determine potential side effects to the nasal mucosa or otherwise clinically relevant intranasal conditions. Vital signs were also measured.

Sample size

For studies MP4002 and MP4004, sample size was determined based on the results of a previously published proof-of-concept exploratory study,²⁰ which

suggested that MP29-02 and FP might reduce the rTNSS by -5.92 and -4.19 , respectively, and that a meta-analysis SD of 5 might be a conservative estimate. On the basis of these values, a 2-sided α value of 5%, and a 10% dropout rate, 195 randomized subjects per treatment arm were sufficient to achieve 90% power. Sample size in study MP4006 was determined by excluding a treatment difference of less than 0.6 units in overall reduction in the rTNSS over a 14-day treatment period. Allowing for dropouts, a minimum of 450 subjects per group had to be randomized.

Randomization

Patients were randomized and balanced by study site in blocks of 4. Eligible subjects received the study site's next available randomization number in sequence.

Blinding

Individual nasal spray bottles were identity masked such that both patients and study personnel were blind to treatment assignment. The active controls comprised the individual components of MP29-02 in the same vehicle (ie, contained the same excipients assessed qualitatively and quantitatively), pump volume (0.137 mL per spray), and device (see the Methods section in this article's Online Repository). A blind randomization code was maintained at a central site apart from the sponsor and study centers. Study blinding was preserved at the study sites until all subjects completed the study and the database had been locked.

Statistical analyses

A hierarchical test procedure was implemented to maintain the overall 2-sided type I error level of .05 among the pairwise comparisons. As a first step, changes in combined rTNSSs were compared between patients receiving MP29-02 and placebo. If this was significant, MP29-02 was then compared with azelastine, and if this was also significant, it was then compared with FP.

As prespecified in trial protocols and statistical analysis plans before unblinding, efficacy analyses were performed on the intent-to-treat population of all randomized patients with at least 1 postbaseline observation. An analysis of covariance (ANCOVA) model was applied to the primary efficacy variable of absolute change in combined morning plus evening rTNSSs. The model included the treatment days from day 2 (first day with postdose morning score) to day 14. Fixed effects were treatment group, day, and center, with baseline as a continuous covariate. The covariance matrix of the error terms was left unspecified and allowed to differ among treatment groups, with degrees of freedom calculated by using the Satterthwaite approximation. Treatment differences are presented as differences in least squares means resulting from this applied ANCOVA (ie, estimates are corrected for influence of covariates, such as center or baseline severity [see Methods section in this article's Online Repository]), to account for the applied inferential statistical methods. Change from baseline in iTNSSs, individual reflective nasal symptom scores, rTOSSs, and RQLQ scores were assessed in the same way.

The meta-analysis on efficacy data was conducted *post hoc* and comprised all 3 studies. The statistical models used for the meta-analysis were similar to those used in the individual studies, with an additional fixed effect for study.

In addition, the rTNSS (overall and by day) was assessed based on patient severity. Patients were categorized into 2 severity groups according to their median baseline rTNSSs (ie, ≤ 18.9 or > 18.9) or median baseline RQLQ scores (ie, ≤ 3.9 or > 3.9). Moreover, time to response was analyzed by using Kaplan-Meier estimates. A change from baseline in (1) combined rTNSS of at least 50%¹⁷ or (2) a score of 1 point or less for each nasal symptom (ie, complete or near-complete resolution of each symptom) were used to define response.

RESULTS

Patients

Study completion rates were high (approximately 95%) and similar across studies and across treatment groups (see Table E2 in this article's Online Repository at www.jacionline.org).

Dropout rates were negligible (see Table E3 in this article's Online Repository at www.jacionline.org). When data were pooled for meta-analysis, 848, 846, 847, and 857 patients received MP29-02, FP, azelastine, and placebo, respectively. The baseline characteristics of the 4 treatment groups were similar, both within and between studies (Table I). Patients' baseline rTNSSs were well matched and confirmed that the vast majority of these patients had moderate-to-severe AR.

Outcomes

Efficacy in individual studies (primary end point rTNSS). In each study MP29-02 significantly reduced the mean rTNSS from baseline by a greater margin than FP, azelastine, or placebo (Table II and Fig 1). All individual nasal symptoms contributed to the effect (see Tables E4 and E5 in this article's Online Repository at www.jacionline.org). In each study all active treatments were statistically significantly superior to placebo, whereas MP29-02 demonstrated superiority to all other treatment arms.

Safety. For each study, the proportion of subjects with a treatment-emergent adverse event was similar for the active groups (see Table E6 in this article's Online Repository at www.jacionline.org). The higher proportion of treatment-related adverse events observed in the MP29-02 and azelastine treatment groups was due primarily to the taste of azelastine coded as dysgeusia in these patients (2.1% to 4.7% of MP29-02-treated patients and 3.4% to 7.2% of azelastine-treated patients, see Table E7 in this article's Online Repository at www.jacionline.org), but no patient discontinued therapy because of this event. For all studies, changes in vital signs and nasal examination were similar in all groups.

Meta-analysis. rTNSSs, iTNSSs, individual symptom scores, and rTOSSs: Change from baseline. Patients treated with MP29-02 experienced significantly greater nasal symptom relief than those treated with either monotherapy. Over the entire 14-day treatment period, MP29-02 reduced the mean rTNSS from baseline (-5.7 [SD, 5.3]) to a significantly greater degree than FP (-5.1 [SD, 4.9], $P < .001$), azelastine (-4.4 [SD, 4.8], $P < .001$), or placebo (-3.0 [SD, 4.2], $P < .001$; Table II and Fig 1). MP29-02 had an onset of action of 30 minutes, and the clinical benefit was observed during the first day of assessment and sustained over the entire course of treatment (see Fig E1 in this article's Online Repository at www.jacionline.org).

MP29-02 reduced the overall iTNSS from baseline to a significantly greater extent than FP ($P = .022$), azelastine ($P < .001$), or placebo ($P < .001$). MP29-02 targeted all of the symptoms of AR (see Tables E4 and E5). Compared with FP or azelastine monotherapy, patients who received MP29-02 had greater relief from their symptoms of nasal congestion ($P = .005$ vs FP and $P < .001$ vs azelastine), nasal itch ($P = .005$ vs FP and $P = .001$ vs azelastine), rhinorrhea ($P = .013$ vs FP and $P < .001$ vs azelastine), and sneezing ($P = .001$ vs FP and $P < .001$ vs azelastine; see Tables E4 and E5). Patients treated with MP29-02 also experienced superior relief from their ocular symptoms than those treated with FP alone. Over the entire 14-day treatment period, MP29-02 reduced the mean rTOSS from baseline (-3.2 [SD, 4.0]) compared with FP (-2.8 [SD, 3.6]), azelastine (-2.9 [SD, 3.8]), or placebo (-1.8 [SD, 3.4]), achieving statistical significance versus FP ($P = .003$) and placebo ($P < .001$; see Tables E4 and E5).

TABLE I. Baseline characteristics of study participants included in 3 randomized trials (ITT population)

Study MP4002				
	MP29-02 (n = 207)	FP (n = 207)	Azelastine (n = 208)	Placebo (n = 209)
Age (y)	37.3 (14.1)	38.6 (14.1)	36.2 (14.6)	37.3 (16.0)
Male sex, no. (%)	65 (31.4)	80 (38.6)	78 (37.5)	77 (36.8)
White race, no. (%)	162 (78.3)	161 (77.8)	162 (77.9)	169 (80.9)
History of SAR (y)	21.7 (13.2)	21.3 (13.5)	21.6 (13.6)	21.2 (14.0)
Study MP4004				
	MP29-02 (n = 193)	FP (n = 189)	Azelastine (n = 194)	Placebo (n = 200)
Age (y)	38.8 (14.1)	37.0 (13.6)	38.2 (13.5)	37.2 (13.0)
Male sex, no. (%)	67 (34.7)	68 (36.0)	66 (34.0)	81 (40.5)
White race, no. (%)	154 (79.8)	140 (74.1)	153 (78.9)	164 (82.0)
History of SAR (y)	21.5 (13.5)	21.1 (13.7)	19.7 (13.1)	21.0 (12.8)
Study MP4006				
	MP29-02 (n = 448)	FP (n = 450)	Azelastine (n = 445)	Placebo (n = 448)
Age (y)	35.6 (14.5)	34.2 (14.5)	36.4 (14.8)	34.7 (14.1)
Male sex, no. (%)	171 (38.2)	170 (37.8)	174 (39.1)	179 (40.0)
White race, no. (%)	364 (81.3)	356 (79.1)	357 (80.2)	348 (77.7)
History of SAR (y)	20.4 (13.0)	19.6 (12.5)	19.5 (12.9)	19.6 (12.4)

Data are presented as means (SDs) unless otherwise stated.
ITT, Intent to treat.

TABLE II. Total nasal symptom scores (baseline and change from baseline) for 3 randomized trials and the meta-analysis results (ITT population)

Treatment	No.	Baseline	Change from baseline	Difference	LS mean	95% CI	P value
Study MP4002							
MP29-02	207	18.3 (3.0)	-5.5 (5.2)	—	—	—	—
FP	207	18.2 (3.2)	-5.0 (4.7)	MP29-02, FP	-0.9	-1.74 to -0.07	.034
AZE	208	18.2 (3.5)	-4.1 (4.6)	MP29-02, AZE	-1.4	-2.22 to -0.54	.002
Placebo	209	18.6 (3.2)	-2.6 (3.9)	MP29-02, PLA	-2.7	-3.48 to -1.91	<.001
				FP, PLA	-1.8	-2.50 to -1.09	<.001
				AZE, PLA	-1.3	-2.04 to -0.60	.001
Study MP4004							
MP29-02	193	18.2 (3.3)	-5.6 (5.2)	—	—	—	—
FP	189	18.6 (2.9)	-5.0 (5.2)	MP29-02, FP	-1.0	-1.91 to -0.05	.038
AZE	194	18.5 (3.1)	-4.4 (4.6)	MP29-02, AZE	-1.0	-1.90 to -0.09	.032
Placebo	200	18.2 (3.1)	-2.8 (3.9)	MP29-02, PLA	-2.5	-3.33 to -1.67	<.001
				FP, PLA	-1.5	-2.34 to -0.69	.001
				AZE, PLA	-1.5	-2.31 to -0.71	.001
Study MP4006							
MP29-02	448	19.4 (2.4)	-5.6 (5.2)	—	—	—	—
FP	450	19.4 (2.4)	-5.1 (4.7)	MP29-02, FP	-0.6	-1.22 to -0.07	.029
AZE	445	19.5 (2.5)	-4.5 (4.8)	MP29-02, AZE	-0.7	-1.30 to -0.13	.016
Placebo	448	19.5 (2.4)	-3.2 (4.3)	MP29-02, PLA	-2.1	-2.70 to -1.57	<.001
				FP, PLA	-1.5	-2.03 to -0.95	<.001
				AZE, PLA	-1.4	-1.96 to -0.87	<.001
Meta-analysis (studies MP4002, MP4004, and MP4006)							
MP29-02	848	18.8 (2.9)	-5.7 (5.3)	—	—	—	—
FP	846	18.9 (2.8)	-5.1 (4.9)	MP29-02, FP	-0.8	-1.18 to -0.34	.001
AZE	847	18.9 (3.0)	-4.4 (4.8)	MP29-02, AZE	-0.9	-1.37 to -0.52	<.001
Placebo	857	19.0 (2.8)	-3.0 (4.2)	MP29-02, PLA	-2.3	-2.75 to -1.95	<.001
				FP, PLA	-1.6	-1.97 to -1.21	<.001
				AZE, PLA	-1.4	-1.78 to -1.02	<.001

Data are expressed as means (SDs). Difference from active treatment is given as LS mean treatment difference with associated 95% CIs and P values.
AZE, Azelastine (137 µg per nostril twice daily); FP, fluticasone propionate (50 µg per nostril twice daily); LS, least squares; MP29-02, azelastine/FP (137/50 µg/nostril twice daily); PLA, placebo.




FIG 1. Effect of MP29-02, FP (FLU), and azelastine (AZE) on overall rTNSSs (morning plus evening) in patients with moderate-to-severe SAR. Data are presented as least squares (LS) mean change from baseline derived by means of ANCOVA minus placebo. The precision of these estimates are indicated by the upper bounds of the respective 95% CIs. *Study MP4002:* n = 831, * $P = .034$ versus FP; † $P = .001$ versus AZE; *Study MP4004:* n = 776, * $P = .038$ versus FP; † $P = .032$ versus AZE; *Study MP4006:* n = 1791, * $P = .029$ versus FP; † $P = .016$ versus AZE; *Meta-analysis:* n = 3398, * $P < .001$ versus FP; † $P < .001$ versus AZE.

rTNSS responder analyses. Fig 2, A, shows the proportion of patients in each treatment group who experienced a 50% or greater reduction in rTNSS over time. The results highlighted a time advantage of MP29-02 over FP (up to 3 days earlier) and azelastine (up to 5 days earlier) monotherapy in producing a clinically meaningful reduction in rTNSS, as well as an increased responder rate with MP29-02 (see Table E8 in this article's Online Repository at www.jacionline.org). More patients treated with MP29-02 (12.4%) also exhibited complete or near-complete elimination of their symptoms (ie, reduction in all nasal symptoms scores to ≤ 1) than those treated with FP (9.3%), azelastine (7.1%), or placebo (4.2%; Fig 2, B). Moreover, this effect was also observed days earlier than either monotherapy: up to 5 days faster than FP ($P = .033$) and up to 7 days faster than azelastine ($P < .001$).

rTNSS change from baseline by baseline patient severity. MP29-02 provided benefits for all patients, providing significantly greater symptom relief than FP or azelastine monotherapy regardless of disease severity (Fig 3). When severity was split by median baseline rTNSS, MP29-02 was significantly superior to FP (difference, -0.6 ; $P = .033$ [95% CI, -1.16 to -0.05]) and azelastine (difference: -0.8 ; $P = .004$ [95% CI, -1.41 to -0.27]) in patients with less severe disease (ie, baseline rTNSS of ≤ 18.9), with a greater benefit observed in patients with more severe disease (ie, baseline rTNSS of >18.9) compared with both FP (difference: -0.8 ; $P = .008$ [95% CI, -1.46 to -0.23]) or azelastine (difference: -1.1 ; $P = .001$ [95% CI, -1.71 to -0.48]). When severity was alternatively split by median baseline RQLQ score, MP29-02 was again superior to FP and azelastine monotherapy (in terms of rTNSS improvement) in patients with moderate rhinitis (ie, RQLQ: ≤ 3.9 ; difference of -0.4 [$P = .159$; 95% CI, -1.01 to 0.17] vs FP and difference




FIG 2. Time-response curves showing the percentage of patients exhibiting 50% improvement in rTNSSs (A) or a score of 1 point or less (ie, complete or near-complete resolution) for each nasal symptom (B) by treatment day after treatment with MP29-02 (n = 834), FP (FLU; n = 846), azelastine (AZE; n = 847), or placebo (PLA; n = 857). Data are presented as mean proportion of patients for the meta-analysis dataset (studies MP4002, MP4004, and MP4006). Fig 2, A, MP29-02 versus FLU: $P = .071$; MP29-02 versus AZE: $P < .001$; MP29-02 versus PLA: $P < .001$. Fig 2, B, MP29-02 versus FLU: $P = .033$; MP29-02 versus AZE: $P < .001$; MP29-02 versus PLA: $P < .001$.

of -0.9 [$P = .006$; 95% CI, -1.46 to -0.24] vs azelastine) and significantly superior in patients with severe rhinitis (ie, RQLQ: >3.9 ; difference of -1.0 [$P = .004$; 95% CI, -1.68 to -0.33] vs FP and difference of -1.1 [$P = .001$; 95% CI, -1.75 to -0.44] vs azelastine).

QoL. Patients were well matched for QoL impairment, with overall baseline RQLQ scores of 3.9 (SD, 1.0) in the MP29-02, azelastine, and placebo groups and 3.8 (SD, 1.0) in the FP group. By day 14, all active treatments significantly improved patient QoL (MP29-02: -1.6 [SD, 1.3]; FP: -1.5 [SD, 1.3]; azelastine: -1.4 [SD, 1.3]) compared with placebo (-1.0 [SD, 1.2], $P < .001$).

DISCUSSION

Before MP29-02, no clinical development program had demonstrated additional benefit over 2 currently recommended first-line AR therapies in patients with moderate-to-severe disease. In the present program MP29-02 demonstrated superior efficacy over intranasal FP and intranasal azelastine monotherapy in patients with AR in a set of 3 randomized, double-blind, placebo-controlled clinical studies with active controls by using the same device and formulation. This provides sound clinical evidence, for the first time, that intranasal antihistamines and corticosteroids have complementary pharmacologic effects on the pathogenesis of AR and satisfy the demands of the Allergic Rhinitis and its Impact on Asthma guidelines requesting high-quality direct comparison studies. The consistency of the results among the clinical trials and symptoms contributes to the robustness of the data. Adverse events were similar for all active groups, and only a few patients experienced mild dysgeusia.

The advancement in the treatment of SAR derives from MP29-02 providing consistent and uniform relief from each of the individual nasal symptoms of congestion, itching, rhinorrhea, and sneezing. Whether intranasal corticosteroids are also effective in treating ocular symptoms is an ongoing debate.²¹ In this regard MP29-02 has been shown to be more effective than FP, as well as placebo, in alleviating ocular symptoms.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.